^
Association details:
| Biomarker: | High NLR |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug Class: | PD-L1 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma
Published date:
10/04/2023
Excerpt:
We identified 135 patients with mUC who received anti-PD1/L1 ICI….Patients with NLR ≥ 4 had a significant worse OS (8.2 months vs 17.7 months P = 0.0001).
DOI:
https://doi.org/10.1101/2023.10.03.23296504
